NBIX » Topics » REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

These excerpts taken from the NBIX 10-K filed Feb 4, 2009.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
The Board of Directors and Stockholders
Neurocrine Biosciences, Inc.
 
We have audited the accompanying consolidated balance sheets of Neurocrine Biosciences, Inc. as of December 31, 2008 and 2007, and the related consolidated statements of income, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2008. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Neurocrine Biosciences, Inc. at December 31, 2008 and 2007, and the consolidated results of its operations and its consolidated cash flows for each of the three years in the period ended December 31, 2008, in conformity with U.S. generally accepted accounting principles.
 
As discussed in Note 1 to the consolidated financial statements, Neurocrine Biosciences, Inc. changed its method of accounting and disclosures for fair value measurements and fair value reporting of financial assets and liabilities in accordance with Statement of Financial Accounting Standards No. 157, Fair Value Measurements, and Statement of Financial Accounting Standards No. 159, the Fair Value Option for Financial Assets and Financial Liabilities — Including an amendment of FASB Statement No. 115.
 
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Neurocrine Biosciences, Inc.’s internal control over financial reporting as of December 31, 2008, based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 2, 2009, expressed an unqualified opinion thereon.
 
/s/  Ernst & Young LLP
 
San Diego, California
February 2, 2009


43


Table of Contents

NEUROCRINE BIOSCIENCES, INC.
 
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM




 



The Board of Directors and Stockholders



Neurocrine Biosciences, Inc.


 



We have audited the accompanying consolidated balance sheets of
Neurocrine Biosciences, Inc. as of December 31, 2008 and
2007, and the related consolidated statements of income,
stockholders’ equity, and cash flows for each of the three
years in the period ended December 31, 2008. These
financial statements are the responsibility of the
Company’s management. Our responsibility is to express an
opinion on these financial statements based on our audits.


 



We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.


 



In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the
consolidated financial position of Neurocrine Biosciences, Inc.
at December 31, 2008 and 2007, and the consolidated results
of its operations and its consolidated cash flows for each of
the three years in the period ended December 31, 2008, in
conformity with U.S. generally accepted accounting
principles.


 



As discussed in Note 1 to the consolidated financial
statements, Neurocrine Biosciences, Inc. changed its method of
accounting and disclosures for fair value measurements and fair
value reporting of financial assets and liabilities in
accordance with Statement of Financial Accounting Standards
No. 157, Fair Value Measurements, and Statement of
Financial Accounting Standards No. 159, the Fair Value
Option for Financial Assets and Financial
Liabilities — Including an amendment of FASB Statement
No. 115
.


 



We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States),
Neurocrine Biosciences, Inc.’s internal control over
financial reporting as of December 31, 2008, based on the
criteria established in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission and our report dated February 2, 2009,
expressed an unqualified opinion thereon.


 



/s/  Ernst &
Young LLP



 



San Diego, California



February 2, 2009





43





Table of Contents







NEUROCRINE
BIOSCIENCES, INC.



 




REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
The Board of Directors and Stockholders
Neurocrine Biosciences, Inc.
 
We have audited the accompanying consolidated balance sheets of Neurocrine Biosciences, Inc. as of December 31, 2007 and 2006, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2007. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
 
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Neurocrine Biosciences, Inc. at December 31, 2007 and 2006, and the results of its consolidated operations and its cash flows for each of the three years in the period ended December 31, 2007, in conformity with U.S. generally accepted accounting principles.
 
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Neurocrine Biosciences, Inc.’s internal control over financial reporting as of December 31, 2007, based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 7, 2008, expressed an unqualified opinion thereon.
 
As discussed in Note #1 to the consolidated financial statements, Neurocrine Biosciences, Inc. changed its method of accounting for Share-Based Payments in accordance with Statement of Financial Accounting Standards No. 123 (revised) on January 1, 2006.
 
/s/ ERNST & YOUNG LLP
 
San Diego, California
February 7, 2008


42


Table of Contents

NEUROCRINE BIOSCIENCES, INC.
 
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM




 



The Board of Directors and Stockholders



Neurocrine Biosciences, Inc.


 



We have audited the accompanying consolidated balance sheets of
Neurocrine Biosciences, Inc. as of December 31, 2007 and
2006, and the related consolidated statements of operations,
stockholders’ equity, and cash flows for each of the three
years in the period ended December 31, 2007. These
financial statements are the responsibility of the
Company’s management. Our responsibility is to express an
opinion on these financial statements based on our audits.


 



We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.


 



In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the
consolidated financial position of Neurocrine Biosciences, Inc.
at December 31, 2007 and 2006, and the results of its
consolidated operations and its cash flows for each of the three
years in the period ended December 31, 2007, in conformity
with U.S. generally accepted accounting principles.


 



We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States),
Neurocrine Biosciences, Inc.’s internal control over
financial reporting as of December 31, 2007, based on the
criteria established in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission and our report dated February 7, 2008,
expressed an unqualified opinion thereon.


 



As discussed in Note #1 to the consolidated financial
statements, Neurocrine Biosciences, Inc. changed its method of
accounting for Share-Based Payments in accordance with Statement
of Financial Accounting Standards No. 123 (revised) on
January 1, 2006.


 



/s/ ERNST & YOUNG LLP


 



San Diego, California



February 7, 2008





42





Table of Contents







NEUROCRINE
BIOSCIENCES, INC.



 




RELATED TOPICS for NBIX:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki